A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer

Trial Profile

A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Tucatinib (Primary) ; Capecitabine; Trastuzumab
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Acronyms Triplet
  • Sponsors Cascadian Therapeutics
  • Most Recent Events

    • 07 Dec 2017 Pooled results of the ONT-380-005/Triplet and ONT-380-004 studies (n = 77) presented in a Cascadian Therapeutics media release.
    • 07 Dec 2017 According to a Cascadian Therapeutics media release, pooled analysis of data from the ONT-380-005/Triplet study and ONT-380-004 studies (n = 77) will be presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top